- Display 15 Products per page
Published: January 1, 2003 | Price: $1,121.00 – $1,717.00
In the summer of 2002, Kalorama Information released a major study on non-psychiatric neurotherapeutic drug markets. At almost 500 pages, the resulting report covered a broad range of neurological agents comprehensively and in depth; however, the breadth and authority of the results proved to be more information than some marketers needed. Smaller biopharmaceutical concerns—some of the real drivers of this market—are more focused on individual neurological disorders such as multiple sclerosis, Alzheimer’s disease, or neurological cancers, rather than the broad...Published: November 1, 2006 | Price: $1,200.00 – $7,000.00
Propelled by advances in molecular biology, the cancer vaccine industry is poised for unprecedented growth. This second edition of Kalorama’s groundbreaking 2003 study completely updates the market data and reviews the technological, clinical, and business trends that have shaped and reshaped this emerging field. Specific segments covered in the report include: Cervical cancer, Colorectal cancer, Lung cancer, Lymphoma, Melanoma, Prostate cancer, and Other cancers for which vaccines are in development. Each market segment provides an overview, descriptions of products available...Published: April 1, 2007 | Price: $1,295.00 – $2,995.00
SMOKING CESSATION IS AN increasingly important area of focus for pharmaceutical companies, healthcare entities and governments. There are 1.4 billion smokers in the world, and smoking is a known cause of heart disease, lung cancer, respiratory infections and many other diseases. This has created a large market for smoking cessation aids. The market, which Zyban currently holds a tenuous lock on, is about to change, with a major new brand ready to shake up the current market share. At the...Published: November 25, 2015 | Price: $1,396.50 – $2,796.50
Transdermal and Transmucosal Drug Delivery Markets Transdermal and Transmucosal Drug Delivery Markets analyzes the current and potential markets for transdermal/transmucosal drug delivery, a well-established accepted route of administration for therapeutically beneficial medicines. Transdermal and Transmucosal Drug Delivery Markets provides the following market information: The Worldwide Market for Transdermal/Transmucosal Drug Delivery Technology and Pharmaceuticals, 2013-2020 The Worldwide Market for Pharmaceuticals Utilizing Transdermal/Transmucosal Drug Delivery Systems by Type, 2013–2020 The Worldwide Market for Pharmaceuticals Utilizing Transdermal/Transmucosal Drug Delivery Technologies, Market Share by...Published: August 1, 2003 | Price: $1,496.00 – $2,992.00
The OTC women’s health market encompasses a wide variety of products that have been determined safe and effective as over-the-counter products. The market is driven by several factors including increasing number of baby boomers entering old age, increasing incidences of diseases; product demand; and several others. In response to many inquiries from readers of Kalorama Information’s March 2003 publication Women’s Health: Worldwide Prescription Drug Markets, 3rd Edition, we embarked on a supplemental study that goes beyond the prescription market to...Published: June 1, 2004 | Price: $1,500.00 – $3,000.00
Biologics, or biopharmaceuticals, are synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies and nucleic acids such as DNA or RNA. Generic products are non-patented chemical and therapeutic equivalents of brand name drugs. However, biogenerics are not generic biologics, because there can technically be no generic form of biologics. That is, the complex process of creating biologics, means that traditional definitions of bioequivalence used in the generic drug industry do not (or may not)...Published: September 1, 2006 | Price: $1,500.00 – $7,000.00
This report focuses on the applications of current and advanced therapeutics to the treatment of psoriasis and psoriatic arthritis, the options they present, and the progress that is being made in these fields. The major market effects of new therapeutics, with the potential of a breakthrough drug always a possibility, are expected to be seen over the next ten years. The technology trends selected in conjunction with the growing interest in psoriasis and its treatment present the most informative picture...Published: November 1, 2007 | Price: $1,500.00 – $7,000.00
Offshoring of clinical trials is increasing as companies in the U.S. are finding challenges in clinical trial research ranging from cost, patient recruitment, patient compliance during participation, qualified professionals, new clinical trial patients, and other problems. This provides an opportunity for BRIC countries and other developing regions to grab a piece of the clinical trial market. Countries such as India and China have a vast population who are interested in taking part in clinical trial research, and these regions can...Published: August 1, 2008 | Price: $1,500.00 – $4,995.00
Alzheimer’s Disease is the most common cause of dementia, constituting 60% to 70% of all cases, and the risk with the disease doubles every 5 years after age 65. Incidence of the disease is increasing, and the resulting attention given to Alzheimer's Disease has encouraged development of new treatments. There is an opportunity for pharmaceutical companies to compete in this market, as Kalorama analyst Melissa Elder outlines in this study. This report includes incidence of Alzheimer’s disease worldwide with information...Published: February 1, 2010 | Price: $1,500.00 – $8,400.00
The global market for human vaccines has experienced strong growth in the past few years, and R&D departments at many pharmaceutical companies are working on new prophylactics, some of which may see near-term marketing. What illnesses may see a vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can current vaccine success stories tell us about the future of the vaccine...Published: September 1, 2010 | Price: $1,500.00 – $3,000.00
Kalorama has been researching and examining the development of cancer vaccines for seven years. In April 2010, the cancer vaccine market experienced one of the biggest achievements in the therapeutic vaccine treatment of cancer—the approval of the prostate cancer vaccine PROVENGE (TM). This, in addition to the success of cervical cancer vaccine products, has created a viable market for what was merely a speculative area just one decade ago. Even with achievements for some companies, numerous vaccines with apparently strong...Published: September 19, 2012 | Price: $1,500.00 – $3,000.00
This report examines the market for vaccines used in humans to previous various types of disease. It covers only commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable; it does not cover emerging vaccines for diseases that are not currently vaccine-preventable, such as Alzheimer’s disease, diabetes, Ebola infection, Epstein-Barr virus (EBV) infection, ETEC infection, heart attach, Helicobacter pylori infection, multiple sclerosis, Parkinson’s disease, West Nile virus (WNV) infection, etc.; vaccines that address these and other not-yet-vaccine-preventable conditions are...Published: May 20, 2013 | Price: $1,500.00 – $2,250.00
The World Market for Pain Management Drugs and Devices encompasses a wide variety of products that treat and ease pain. The field of pain management is currently experiencing a busy and interesting period; and as a result, the range of therapeutic options available to physicians and other clinicians has expanded. Solutions to pain disorders are still elusive but continued human and animal studies will help to further identify the biochemical and neurophysiological factors that influence pain. The future of pain...Published: April 1, 2003 | Price: $1,875.00 – $3,750.00
This report analyzes the world markets for human antiviral medications, focusing on the current market for and the development of drugs that are used to directly combat and treat viruses viral infections. For the purposes of this report, antivirals are drugs used to directly treat viral infection after it occurs. The report does not discuss products for the prevention of viral infection—that is, adult or pediatric vaccinations—and does not discuss other diseases, such as cancer or heart disease, that may...Published: April 1, 2003 | Price: $1,875.00 – $3,750.00
Each year in the United States, more than 500,000 people with coronary artery disease are treated with percutaneous transluminal coronary angioplasty (PTCA). Unfortunately, restenosis occurs within three to six months in 40% to 50% of PTCA patients due to either thrombosis or abnormal tissue growth. As a result, restenosis constitutes the major limitation to the effectiveness of PTCA. To improve on this condition, medical science created stents in an attempt to keep coronary arteries open. However, one of the early...